Caribou Biosciences, Inc. Common Stock (CRBU)
Caribou Biosciences, Inc. is a biotechnology company focused on developing gene-editing technologies using CRISPR-Cas3 and other CRISPR-based tools. Founded in 2011, it specializes in precision gene editing for applications in agriculture, human therapeutics, and industrial biotechnology. The company's platform aims to enable more efficient, accurate, and versatile genetic modifications to address various biological challenges.
Company News
CRISPR therapies are showing significant potential with over 25 key companies developing 30+ pipeline therapies targeting genetic disorders, with promising clinical trials across various disease areas.
During the last three months, 5 analysts shared their evaluations of Caribou Biosciences (NASDAQ:CRBU), revealing diverse outlooks from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding month...
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of -17.95% and 19.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Investors didn't like the clinical-stage biotech's Q4 update for one key reason.